Ads
related to: biotech and pharma
Search results
Earnings call: Innate Pharma reveals Q1 2024 results and pipeline progress By Investing.com
Investing.com· 4 days agoInnate Pharma SA (OTC:IPHYF) (IPHA) discussed its first quarter 2024 financial results and provided...
Earnings call: Moleculin Biotech optimistic on Annamycin's future By Investing.com
Investing.com· 5 days agoMoleculin Biotech, Inc. (NASDAQ:MBRX), in its first quarter 2024 earnings call, highlighted...
The M&A pool set to accelerate biotech innovation
Endpoints News· 6 days agoQ1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. RBC’s biotech investment banking ...
Earnings call: Imunon reports on Q1 2024, optimistic about cancer treatment By Investing.com
Investing.com· 5 days agoThe biotechnology company, which specializes in developing immunotherapy treatments, introduced...
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks via Yahoo Finance· 3 days agoAs the earnings come to an end in the ongoing reporting cycle, the focus shifts to pipeline and...
UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
GuruFocus.com via Yahoo Finance· 6 days agoInvestors and stakeholders will likely keep a close watch on the ENVISION trial results, which could...
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks via Yahoo Finance· 2 days agoWatch this space for regular pipeline and regulatory updates next week. J&J, Lilly, Novo Nordisk and...
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales
Morningstar· 6 days agoBy Dean Seal Legend Biotech narrowed its loss in the first quarter as revenue climbed on higher sales of its multiple myeloma treatment Carvykti. The cell therapy company ...
Is Viking Therapeutics the Best Biotech Stock for You?
Motley Fool via Yahoo Finance· 6 days agoThough it has yet to commercialize a drug, unlike its primary big pharma competitors, the data about...
Earnings call: Lumos Pharma gears up for Phase 3 trial of LUM-201 By Investing.com
Investing.com· 3 days agoThe company has completed a constructive End-of-Phase 2 Meeting with the FDA and is planning to...